By Stephen Nakrosis
Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma.
Opdivo, or nivolumab, plus Yervoy, or ipilimumab, was approved as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma, the company said Friday. HCC is the most common primary liver cancer, according to the company.
The company also said Phase 3 trial results showed Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to the investigator's choice of lenvatinib or sorafenib.
The combination treatment received accelerated approval from the FDA in 2020 and has been an established second-line treatment for patients with advanced HCC who were previously treated with sorafenib.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 11, 2025 16:33 ET (20:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.